Staff reports of setting events associated with challenging behavior.

Behav Modif

University of Kent at Canterbury, Tizard Centre, Canterbury, Kent, UK CT2 7LZ.

Published: April 2003

This study identified the setting events reported by caregivers as more and less likely to be associated with challenging behaviors of people with intellectual disabilities. Sixty-five staff working with 22 individuals were interviewed using a setting event inventory. Some setting events (e.g., being in a crowded room) were reported as strongly associated with challenging behavior, some (e.g., one-to-one support) as strongly associated with its absence. Some (e.g., day of week) were reported to be largely "inert"; many were idiosyncratically associated with occurrence, absence, or inertness. Different categories of setting events contributed different amounts to reported variation in challenging behavior. The inventory described here, or modified versions, may help identify relationships between setting events and challenging behaviors. The relationships reported in this study suggest ways in which service provision might be modified to help prevent challenging behavior.

Download full-text PDF

Source
http://dx.doi.org/10.1177/0145445503251604DOI Listing

Publication Analysis

Top Keywords

setting events
20
challenging behavior
16
associated challenging
12
challenging behaviors
8
setting
6
challenging
6
events
5
associated
5
reported
5
staff reports
4

Similar Publications

Introduction: Adults with relapsed or refractory Philadelphia chromosome-positive B-cell precursor acute lymphoblastic leukaemia (R/R Ph+ BCP-ALL) have a dismal outcome. Blinatumomab as a single agent has shown activity in R/R Ph- BCP-ALL, and second or third-generation tyrosine kinase inhibitors (TKIs) can produce high remission rates in Ph+ leukaemias. We aimed to assess the activity of blinatumomab and TKI in combination with intensive chemotherapy in the relapsed or refractory setting.

View Article and Find Full Text PDF

Background: There are adverse effects on the health outcomes of workers whose occupation involves prolonged standing, such as lower back pain, leg pain, cardiovascular diseases, fatigue, discomfort, and pregnancy-related health outcomes. The effectiveness of massage therapy as an intervention for managing leg pain associated with prolonged standing needs to be addressed.

Aims: This study aimed to evaluate the smart dynamic fabric actuator's effectiveness in treating chronic musculoskeletal leg pain in persons with occupations involving prolonged standing.

View Article and Find Full Text PDF

Background: Healthcare adverse events (AEs) significantly impact professionals, often leading to emotional distress and lasting effects. This study investigates the impact of AEs on healthcare professionals in Romania, focusing on nurses to examine their experiences within the patient safety culture and the psychological consequences of AEs. With a limited body of research on patient safety, adverse events, and second victims (SVs) in Romania, this study addresses a crucial gap, highlighting the need for enhanced safety culture and support mechanisms for SVs.

View Article and Find Full Text PDF

Background: Recent studies revealed an association between small kidney volume and progression of kidney dysfunction in particular settings such as kidney transplantation and transcatheter aortic valve implantation. We hypothesized that kidney volume was associated with the incidence of kidney-related adverse outcomes such as worsening renal function (WRF) in patients with acute heart failure (AHF).

Methods: This study was a single-center retrospective cohort study.

View Article and Find Full Text PDF

Background: Alirocumab is a fully human monoclonal antibody to proprotein convertase subtilisin kexin type 9 used for the reduction of low-density lipoprotein cholesterol (LDL-C) in high-risk patients not reaching their LDL-C target. Recently, a 2-mL prefilled autoinjector has been developed to support the monthly 300-mg dosing regimen with a single-injection administration.

Methods And Objectives: Monthly application of 300 mg AlirRocumab (Praluent) using the 2-mL SYDNEY Device (MARS) is a non-interventional, open, prospective, multi-center cohort study conducted in Germany between 2021 and 2023 with an observational period of 12 weeks.

View Article and Find Full Text PDF

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!